H951-MENONCT07751029
Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 31 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 22 words
- Primary and study completion pushed from Oct 2026 to Dec 2026
- Start date changed from estimate of Sep 21, 2026 to Oct 26, 2026
- Notable Recruitment opened
- Primary completion date: Sep 2026 to Oct 2026
- Start date: Aug 2026 to Sep 21, 2026
- Site details revised
- Minor Site contact updated
- Collaborators revised (2)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Vasomotor Symptom Episode
Timeframe: Baseline to Day 30
Secondary (1)
Sleep
Arms and interventions
Haelan 951Experimental
Participants will receive Haelan 951, a fermented soy conventional food product, for 30 consecutive days. Following an in-person screening and baseline visit, participants will complete the study using a decentralized, site-anchored hybrid model with electronic patient-reported outcome (ePRO) assessments, wearable device monitoring, and scheduled remote follow-up.
Dietary supplements: Haelan 951
Sites
1 site in 1 country
- Spectrum Clinical ResearchKansas City, Missouri, United States